Non-invasive treatment of sarcoma

Precise radiotherapy is the most important method of cancer treatment. Precise radiotherapy techniques represented by rapid front knife, proton knife, heavy ion, etc., can perform radical surgery and auxiliary treatment for cancer patients. To understand the progress of radiotherapy, sarcoma is more common in young people, is a malignant tumor derived from mesenchymal tissue (including connective tissue and muscle). Sarcomas are highly malignant and develop rapidly! Common sarcomas include osteosarcoma, leiomyoma, lymphosarcoma, synovial sarcoma, etc.   
The preferred method of sarcoma is surgery. In order to seek a radical cure, domestic doctors usually require patients to have their limbs amputated. , Most patients are difficult to treat. Sarcoma is not sensitive to chemotherapyOrdinary radiotherapy is also difficult to kill tumors, and leiomyoma, lymphosarcoma, and synovial sarcoma are prone to metastasis through the blood. Therefore, the treatment of sarcoma must be as soon as possible and as soon as possible.

The EDGE Radiosurgery system (EDGE radiosurgery tumor treatment system) was developed by the American Varian company and was approved by the US FDA on January 23, 2013. The EDGE blade is by far the most effective non-invasive tumor removal technology, using the unique FDA’s Calypso® GPS for the Body® system and surface beam monitoring system approved on July 21, 2014 with high-frequency real-time dynamics of up to 10 ms Monitor and lock the tumor “escape” during the treatment process, combined with the new generation IGRT and other image guidance technology, using the unique high-intensity HD-MLC collimator up to 2400MU / min to remove tumor tissue with sub-millimeter accuracy with almost no residue . 

The unique characteristics of EDGE speed knife, high-intensity radiation of up to 2400MU / min, can quickly break the DNA of tumor cells, and eventually cause the tumor cells to die, and the tumor is absorbed or scarred. The accuracy of the EDGE knife is as high as 0.1mm. 

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

  • Comments Closed
  • April 28th, 2020

Latest treatment option in uterine cancer

Previous Post:
nxt-post

Palbociclib for the treatment of sarcoma

Next Post:

Scan the code